Spinal muscular atrophy (SMA):
- 21 May 2012
New research brings us closer to understanding the cause of spinal muscular atrophy Researchers in the US have uncovered further clues about why having low levels of the SMN protein causes the symptoms seen in spinal muscular atrophy (SMA). - 30 April 2012
Positive results from phase 1 safety trial of SMA drug Repligen has just announced positive results from its phase 1 safety trial of RG3039 for spinal muscular atrophy. - 6 January 2012
Gene therapy clinical trial for spinal muscular atrophy started Isis Pharmaceuticals has started a Phase 1 clinical trial of an antisense oligonucleotide drug called ISIS-SMNRx in patients with spinal muscular atrophy (SMA). - 29 November 2011
Collaboration offers new hope for potential spinal muscular atrophy treatment Roche has signed a multi-million dollar agreement with PTC Therapeutics to develop drugs for spinal muscular atrophy - 10 November 2011
Highlights from the World Muscle Society Congress Our Director of Research, Dr Marita Pohlschmidt and Head of Grants, Dr Julia Ambler, attended the World Muscle Society congress and here they summarise their highlights. - 7 October 2011
How to find a PA? Vik Shah shares his 21st Century approach of choosing a PA that fits his individual needs. - 27 September 2011
NICE accredit Duchenne guidelines as produced by the highest standards We are delighted to announce that the process used to produce The Duchenne Standards of Care has been formally approved under the NHS Evidence Accreditation Scheme (provided by NICE). - 19 July 2011
Clinical trial for spinal muscular atrophy now recruiting in the UK A clinical trial to test a drug called olesoxime in SMA patients has started in seven European countries including three centres in the UK. - 24 May 2011
New clinical trial for SMA gets go-ahead The US Food and Drug Administration (FDA) has given the go-ahead to pharmaceutical company RepliGen to start a new clinical trial for spinal muscular atrophy. - 21 March 2011
Breakthrough in drug delivery may benefit people with muscle disease Research part-funded by the Muscular Dystrophy Campaign has reported a new way of delivering drugs which was especially effective for the brain.
